Background: Patients with multiple sclerosis (MS) who are of African descent experience a more aggressive disease course than patients who are of white race/ethnicity. In phase 3 clinical trials (Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Sclerosis [AFFIRM] and Safety and Efficacy of Natalizumab in Combination With Interferon Beta-1a in Patients With Relapsing Remitting Multiple Sclerosis [SENTINEL]), natalizumab use significantly improved clinical and magnetic resonance imaging outcomes over 2 years in patients with relapsing MS. Because patients of African descent may be less responsive to interferon beta treatment than patients of white race/ethnicity, the efficacy of natalizumab therapy in this population is clinically important.
Objective: To evaluate the efficacy of natalizumab use in patients of African descent with relapsing MS.
Design: Post hoc analysis.
Setting: Academic research.
Patients: Patients of African descent with relapsing MS who received natalizumab or placebo in the phase 3 AFFIRM study and those who received natalizumab plus intramuscular interferon beta-1a or placebo plus intramuscular interferon beta-1a in the phase 3 SENTINEL study.
Main Outcome Measure: Efficacy of natalizumab use in patients of African descent with relapsing MS who participated in the AFFIRM or SENTINEL trial.
Results: Forty-nine patients of African descent participated in AFFIRM (n = 10) or SENTINEL (n = 39). Demographic and baseline disease characteristics were similar between patients treated with natalizumab (n = 21) or placebo (n = 28). Natalizumab therapy significantly reduced the annualized MS relapse rate by 60% (0.21 vs 0.53 in the placebo group, P = .02). Compared with placebo use, natalizumab therapy also significantly reduced the accumulation of lesions observed on magnetic resonance imaging over 2 years: the mean number of gadolinium-enhancing lesions was reduced by 79% (0.19 vs 0.91, P = .03), and the mean number of new or enlarged T2-weighted lesions was reduced by 90% (0.88 vs 8.52, P = .008).
Conclusion: Natalizumab therapy significantly improved the relapse rate and accumulation of brain lesions in patients of African descent with relapsing MS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneurol.2011.45 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nevus of Hori in African patients: an entity that is most likely underdiagnosed in clinical practice.
Int J Womens Dermatol
March 2025
Private Practice, Pretoria, South Africa.
Background: Nevus of Hori (HN) has been primarily reported in patients of Eastern Asian descent, with a paucity of data regarding HN occurring in African patients. In this study, we report on South African patients with HN initially thought to have melasma.
Objective: To characterize the histopathological and clinical phenotypes of HN in African patients.
Breast cancer is a significant health challenge worldwide, and disproportionately affects women of African ancestry (AA) who experience higher mortality rates relative to other racial/ethnic groups. Several studies have pointed to biological factors that affect breast cancer outcomes. A recently discovered stromal cell population that expresses P ROCR, Z EB1 and P DGFRα (PZP cells) was found to be enriched in normal healthy breast tissue from AA donors, and only in tumor adjacent tissues from donors of European ancestry (EA).
View Article and Find Full Text PDFMental health disparities result from complex factors, including differential diagnoses, lack of access to standard mental health treatments, and inconsistent application of treatments when care is accessed. The COVID-19 pandemic exacerbated these disparities as marginalized groups had less access to testing and care while having higher infection rates. Community-based forms of care, such as music and mindfulness, are affordable and accessible options that can potentially address present mental health disparities.
View Article and Find Full Text PDFKnowledge of Sickle Cell Disease, Awareness of Sickle Cell Trait Status and Its Impact on Relationships Among Students at a Historically Black College.
Hemoglobin
January 2025
Howard University College of Pharmacy, Washington, DC, USA.
Sickle cell disease (SCD) primarily affects people of African American descent in the United States. Many individuals do not know their sickle cell trait (SCT) status or might not be aware of SCD. The purpose of this study was to assess SCD knowledge, awareness of SCT status, and its impact on relationships.
View Article and Find Full Text PDFSarcoidosis is a multisystem disease process with a bimodal distribution typically affecting African American women and those of Scandinavian descent characterized by noncaseating granulomatous disease. We present a case of a 29-year-old African American male patient who was seen in the clinic for recurrent symptomatic cholelithiasis. He had no past medical history or symptoms besides intermittent postprandial right upper quadrant (RUQ) pain with imaging confirming cholelithiasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!